These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 20935677)

  • 1. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
    Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
    Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
    Zhang X; Ding L; Kang L; Wang ZY
    PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells.
    Zhang XT; Ding L; Kang LG; Wang ZY
    Oncol Rep; 2012 Jun; 27(6):2057-65. PubMed ID: 22426783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
    Zhang X; Deng H; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma.
    Qu C; Wang C; Li H; Li Y; Han C; Tao X; Guan X; Zhang Y; Chen M; Liu J; Zou W
    Cell Biol Int; 2022 Nov; 46(11):1759-1774. PubMed ID: 35930599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.
    Kang L; Guo Y; Zhang X; Meng J; Wang ZY
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):262-8. PubMed ID: 21907803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
    Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY
    PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
    Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
    J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ER-α36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells.
    You H; Meng K; Wang ZY
    Steroids; 2018 Jun; 134():78-87. PubMed ID: 29481815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
    Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
    PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
    Wang ZY; Yin L
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel anticancer agent Broussoflavonol B downregulates estrogen receptor (ER)-α36 expression and inhibits growth of ER-negative breast cancer MDA-MB-231 cells.
    Guo M; Wang M; Deng H; Zhang X; Wang ZY
    Eur J Pharmacol; 2013 Aug; 714(1-3):56-64. PubMed ID: 23769740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
    Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
    PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
    Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
    PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
    Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
    Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells.
    Pan X; Zhao B; Song Z; Han S; Wang M
    J Pharmacol Sci; 2016 Feb; 130(2):85-93. PubMed ID: 26810571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.